Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) announced that its development program for Pompe disease will be featured in an oral presentation and two posters at the 2022 MDA Clinical & Scientific Conference. The oral presentation titled Long-term follow-up of cipaglucosidase alfa/miglustat is scheduled for March 16, 2022. In addition, two posters will discuss Immunogenicity of cipaglucosidase alfa versus alglucosidase alfa and the impact of COVID-19 on patients living with Pompe disease. Presentations will be available on the company’s website after the conference.

Positive

• Oral presentation scheduled at a significant conference, providing visibility for the company's research.
• Presentation covers long-term efficacy data of cipaglucosidase alfa/miglustat, potentially enhancing investor confidence.
• Two posters highlight key studies related to immunogenicity and patient experiences, broadening the company's research exposure.

Negative

• None.

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2022 MDA Clinical & Scientific Conference, being held March 13-16, 2022 in Nashville, TN and virtually.

Oral Platform Presentation:
Wednesday, March 16, 12:10 p.m. CST

• Abstract Title: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: an open-label Phase I/II study (ATB200-02)                
  Presenter: Barry Byrne, MD, PhD, University of Florida Health, Gainesville, FL, U.S.A.
  Location: Tennessee Ballroom

Poster Presentations:

• Abstract Title: Immunogenicity of cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset pompe disease: A phase III, randomized study (PROPEL)                  
  Presenter: Tahseen Mozaffar, MD, University of California, Irvine, CA, U.S.A.                  
  Location: Ryman Exhibit Hall B1-2, Poster #65

• Abstract Title: Living with Pompe disease in the UK: Characterizing the patient journey; burden on physical and emotional quality of life; and impact of COVID-19                  
  Presenter: Derralynn Hughes, BMBCh, University College London, London, U.K.
  Location: Virtual

The posters and presentation will be made available on the Amicus website following their respective presentations at the conference.

For more information on the 2022 MDA Clinical & Scientific Conference, please visit www.mdaconference.org.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

FAQ

When is the Amicus Therapeutics oral presentation at the 2022 MDA Clinical & Scientific Conference?

The oral presentation will be held on March 16, 2022, at 12:10 p.m. CST.

What topics will Amicus Therapeutics present at the 2022 MDA Clinical & Scientific Conference?

Topics include long-term follow-up of cipaglucosidase alfa/miglustat, immunogenicity studies, and the impact of COVID-19 on patients with Pompe disease.

Where can I find the Amicus Therapeutics presentations after the conference?

The presentations will be available on the Amicus Therapeutics website following the conference.

What is the focus of Amicus Therapeutics in relation to Pompe disease?

Amicus Therapeutics is focused on developing novel treatments for Pompe disease, highlighted through their research presentations.